Industry News
Biotechnology Industry News
Former CytoDyn CEO Nader…
Former CytoDyn CEO Nader Pourhassan, Ph.D., has received a 30-month prison sentence, or two and a half years, after being convicted on charges related to defrauding biotech investors.
AstraZeneca is showing no signs of…
AstraZeneca is showing no signs of restarting a 200 million pound sterling ($273 million) investment in its hometown, despite keeping its options open.
As the Trump administration erodes…
As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans to pull away from late-stage clinical trial investments in the area.
Despite remaining a fertile…
Despite remaining a fertile hunting ground for Big Pharmas to snap up biotechs or license new therapies, the U.K. hasn’t produced any new publicly listed drug developers of its own for many years.
Sanofi has reported mixed phase 3…
Sanofi has reported mixed phase 3 data on amlitelimab, further muddying the prospects of a molecule tipped to generate blockbuster sales.
Bristol Myers Squibb added a big…
Bristol Myers Squibb added a big name to its executive roster with the appointment of Harald Hampel, M.D., Ph.D. as its new SVP and worldwide head of medical affairs, neuroscience. Hampel comes to BMS after
Hoth Therapeutics has shared phase…
Hoth Therapeutics has shared phase 2 results on its treatment of EGFR inhibitor-induced skin toxicities, ticking off another milestone for a candidate designed to complement cancer therapies.
In a reminder of the money still…
In a reminder of the money still available for enticing obesity assets, Corxel Pharmaceuticals has raised $287 million in series D funds to bankroll phase 2 studies of its oral GLP-1 receptor agonist.
Corcept Therapeutics’…
Corcept Therapeutics’ relacorilant has improved overall survival in a phase 3 ovarian cancer study, building on interim data published last year to give the biotech momentum heading into an FDA approval ruling.
Bristol Myers Squibb will pay…
Bristol Myers Squibb will pay T-cell engager company Janux Therapeutics $50 million in the near term as part of a collaboration to work on a novel tumor-activated therapeutic.
After a short delay and concerns…
After a short delay and concerns of potential intervention from senior officials, the FDA has issued a draft guidance for the industry on the potential use of minimal residual disease and complete response to support
Novo Nordisk has found a buyer for…
Novo Nordisk has found a buyer for cell therapy technologies dropped in its retreat from the modality.
Cancer imaging company Kuva Labs…
Cancer imaging company Kuva Labs is expanding its scope via the acquisition of solid tumor biotech Lisata Therapeutics.
Only four months after IO Biotech…
Only four months after IO Biotech decided to halve its head count, the Danish biotech is already considering whether it must resort to further layoffs.
AI-powered drug developer Insilico…
AI-powered drug developer Insilico Medicine is set for a $10 million upfront payment from a fresh-faced Chinese biotech for half of the rights to a brain-penetrant NLRP3 inhibitor.
For the second year in a row,…
For the second year in a row, flashes of pink cut through the sea of navy, gray and black that flooded San Francisco’s Union Square during the J.P. Morgan Annual Healthcare Conference. The color—largely worn
Riding a regulatory win for its…
Riding a regulatory win for its base editing candidate, Beam Therapeutics is “putting all of our eggs” in the in vivo delivery basket, CEO John Evans said.
Two former executives at Spero…
Two former executives at Spero Therapeutics have agreed to settle with the Securities and Exchange Commission for allegedly misleading investors about the efficacy of the biotech’s lead antibiotic candidate, with a total fine of $187,500.
Tanabe Pharma America’s small…
Tanabe Pharma America’s small molecule designed to boost melanin production has hit the main goal of a phase 3 trial for patients with rare hereditary disorders that cause extreme sensitivity to sunlight.
Pfizer is paying $30 million to…
Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the pharma’s vaccine programs, with hundreds of millions of dollars in potential milestones tied to the deal.